Role of CD97stalk and CD55 as molecular markers for prognosis and therapy of gastric carcinoma patients

Journal of Zhejiang University: Science

Volumn 6 B, Issue 9, 2005, Pages 913-918

  Liu, Yong ^a,b   Chen, Li ^b   Peng, Shu You ^b   Chen, Zhou Xun ^c   Hoang Vu, C ^c  

^a YANGZHOU UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

CD55; CD97stalk; Gastric carcinoma; Molecular markers

Indexed keywords

BIOMARKERS; DIAGNOSIS; DISEASES; ONCOLOGY;

CD55; CD97; GASTRIC CARCINOMA; MOLECULAR MARKERS;

TUMORS;

CD97 PROTEIN, HUMAN; DECAY ACCELERATING FACTOR; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; MESSENGER RNA; RNA; TUMOR MARKER;

ARTICLE; CANCER STAGING; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; STOMACH TUMOR; TISSUE DISTRIBUTION;

ANTIGENS, CD; ANTIGENS, CD55; BASE SEQUENCE; FEMALE; GENE EXPRESSION; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RNA, MESSENGER; RNA, NEOPLASM; STOMACH NEOPLASMS; TISSUE DISTRIBUTION; TUMOR MARKERS, BIOLOGICAL;

EID: 26844562558     PISSN: 10093095     EISSN: None     Source Type: Journal    
DOI: 10.1631/jzus.2005.B0913     Document Type: Article

References (19)

1. Aust, G., Eichler, W., Laue, S., Lehmann, I., Heldin, N.E., Lotz, O., Scherbaum, W.A., Dralle, H., Hoang-Vu, C., 1997. CD97: A dedifferentiation marker in human thyroid carcinomas. Cancer Res., 57: 1798-1806.
2. Aust, G., Steinert, M., Schutz, A., Boltze, C., Wahlbuhl, M., Hamann, J., Wobus, M., 2002. CD97, but not its closely related EGF-TM7 family member EMR2, is expressed on gastric, pancreatic, and esophageal carcinomas. Am. J. Clin. Pathol., 118(5): 699-707.
3. Boltze, C., Schneider-Stock, R., Aust, G., Mawrin, C., Dralle, H., Roessner, A., Hoang-Vu, C., 2002. CD97, CD95 and Fas-L clearly discriminate between chronic pancreatitis and pancreatic ductal adenocarcinoma in perioperative evaluation of cryocut sections. Pathol. Int., 52: 83-88.
4. Brabletz, T., Jung, A., Hermann, K., Gunther, K., Hohenberger, W., Kirchner, T., 1998. Nuclear overexpression of the oncoprotein beta-catenin in colorectal cancer is localized predominantly at the invasion front. Pathol. Res. Pract., 194: 701-704.
5. Brabletz, T., Jung, A., Reu, S., Porzner, M., Hlubek, F., Kunz-Schughart, L.A., Knuechel, R., Kirchner, T., 2001. Variable beta-catenin expression in colorectal cancers indicates tumor progression driven by the tumor environment. Proc. Natl. Acad. Sci. USA, 98: 10356-10361.
6. Hamann, J., Vogel, B., van Schijndel, G.M., van Eier, R.A., 1996. The seven-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J. Exp. Med., 184(3): 1185-1189.
7. Hoang-Vu, C., Bull, K., Schwarz, I., Krause, G., Schmutzler, C., Aust, G., Dralle, H., 1999. Regulation of CD97 protein in thyroid carcinoma. Clin. Endocrinol. Metab., 84: 1104-1109.
8. Jaspars, L.H., Vos, W., Aust, G., van Lier, R.A., Hamann, J., 2001. Tissue distribution of the human CD97 EGF-TM7 receptor. Tissue Antigens, 57: 325-331.
9. Kwakkenbos, M.J., Kop, E.N., Stacey, M., Gordon, S., Lin, H.H., Hamann, J., 2004. The human EGF-TM7 family: A postgenomic view. Immunogenetics, 55: 655-666.
10. Li, L., Spendlove, I., Morgan, J., Durrant, L.G., 2001. CD55 is over-expressed in the tumour environment. Br. J. Cancer, 84(1): 80-86.
11. Maruyama, K., Ochiai, A., Akimoto, S., Nakamura, S., Baba, S., Moriya, Y., Hirohashi, S., 2000. Cytoplasmic beta-catenin accumulation as a predictor of hematogenous metastasis in human colorectal cancer. Oncology, 59: 302-309.
12. Mcknight, A.J., Gordon, S., 1998. The EGF-TM7 family: Unsual structures at the leukocyte surface. Leukoc. Biol., 63: 271-280.
13. Mustafa, T., Klonisch, T., Hombach-Klonisch, S., Kehlen, A., Schmutzler, C., Koehrle, J., Gimm, O., Dralle, H., Hoang-Vu, C., 2004. Expression of CD97 and CD55 in human medullary thyroid carcinomas. Int. J. Oncol., 24(2): 285-294.
14. Niehans, G.A., Cherwitz, D.L., Staley, N.A., Knapp, D.J., Dalmasso, A.P., 1996. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am. J. Pathol., 149(1): 129-142.
15. Nowicki, S., Nowicki, B., Pham, T., Hasan, R., Nagamani, M., 2001. Expression of decay accelerating factor in endometrial adenocarcinoma is inversely related to the stage of tumor. Am. J. Reprod. Immunol., 46(2): 144-148.
16. Remmele, W., Stegner, H.E., 1987. Recommendation for uniform definition of an immunoreactive score (1RS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe, 8: 138-140.
17. Shimo, K., Mizuno, M., Nasu, J., Hiraoka, S., Makidono, C., Okazaki, H., Yamamoto, K., Okada, H., Fujita, T., Shiratori, Y., 2004. Complement regulatory proteins in normal human esophagus and esophageal squamous cell carcinoma. Gastroenterol. Hepatol., 19(6): 643-647.
18. Steinert, M., Wobus, M., Boltze, C., Schutz, A., Wahlbuhl, M., Hamann, J., Aust, G., 2002. Expression and regulation of CD97 in colorectal carcinoma cell lines and tumor tissues. Am. J. Pathol., 161: 1657-1667.
19. Wobus, M., Vogel, B., Schmucking, E., Hamann, J., Aust, G., 2004. N-glycosylation of CD97 within the EGF domains is crucial for epitope accessibility in normal and malignant cells as well as CD55 ligand binding. Int. J. Cancer, 112: 815-822.